tezosentan
Sign in to saveTezosentan is a non-selective ETA and ETB receptor antagonist. It acts as a vasodilator and was designed by Actelion as a therapy for patients with acute heart failure. However, studies showed that tezosentan did not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.
Research
199 papers- Repurposing of the Drug Tezosentan for Cancer Therapy.Current issues in molecular biology · 2023
- Tezosentan in the treatment of acute heart failure.The Annals of pharmacotherapy · 2003
- Tezosentan in the management of decompensated heart failure.Cardiology in review · 2005
- Tezosentan. Actelion/Genentech.Current opinion in investigational drugs (London, England : 2000) · 2003
- Tezosentan attenuates organ injury and mesenteric blood flow decrease in endotoxemia and cecal ligation and puncture.The Journal of surgical research · 2007
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 605.181
Show 4 more facts
- chemical formula
- C₂₇H₂₇N₉O₆S
- canonical SMILES
- CC(C)C1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC
- subject has role
- vasodilator agent
- Commons category
- Tezosentan
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Tezosentan is a non-selective ETA and ETB receptor antagonist. It acts as a vasodilator and was designed by Actelion as a therapy for patients with acute heart failure. However, studies showed that tezosentan did not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.
== References ==
Excerpted from Wikipedia’s “tezosentan” article, available under the CC BY-SA 4.0 licence.